Not available in US and UK media
Kerendia is a non-steroidal, selective mineralocorticoid receptor (MR) antagonist that has been shown to block the deleterious effects of MR overactivation. MR overactivation leads to CKD progression and cardiovascular injury, which may be driven by metabolic, hemodynamic, or inflammatory and fibrotic factors.
Chronic kidney disease (CKD) is a common and potentially fatal condition that is widely underrecognized. The progression of chronic kidney disease is silent and unpredictable, with many symptoms not appearing until the disease is severely advanced. CKD is one of the most common complications of diabetes and an independent risk factor for cardiovascular disease. Up to 40% of people with type 2 diabetes have chronic kidney disease. Despite guideline-directed therapy, patients with CKD and T2D remain at high risk for CKD progression and cardiovascular events. CKD is estimated to affect more than 190 million people with T2D worldwide. Chronic kidney disease in type 2 diabetes is the leading cause of end-stage renal disease, requiring dialysis or a kidney transplant to sustain life. Patients with Chronic Kidney Disease and Type 2 Diabetes were three times more likely to die from cardiovascular-related causes than those with Type 2 Diabetes alone. About Bayer’s commitment in the field of cardiovascular and kidney diseases
Bayer is an innovative leader in the field of cardiovascular diseases, and has long been committed to bringing a better life to mankind by advancing innovative treatment combinations. The heart and kidneys are closely linked in health and disease, and Bayer is working in a broad therapeutic area on new treatments for cardiovascular and kidney diseases, which have unmet medical needs. Bayer’s cardiology franchise already includes multiple products and several other compounds in various stages of preclinical and clinical development. Together, these products reflect the company’s research approach, which prioritizes targets and pathways that have the potential to impact the way cardiovascular disease is treated. About Bayer
Bayer is a global company with core competencies in life sciences, including healthcare and nutrition. Its products and services are designed to help people and the planet thrive by supporting the major challenges posed by a growing and aging global population. Bayer is committed to promoting sustainable development and having a positive impact on its business. At the same time, the Group aims to increase profitability and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality all over the world. In fiscal year 2021, the group has about 100,000 employees and sales of 44.1 billion euros. Pre-Project R&D Expenses For more information, please visit https://pharma.bayer.com
Follow us on Facebook: http://www.facebook.com/bayer
Follow us on Twitter: @BayerPharma Forward-looking statements
This press release may contain forward-looking statements that are based on current assumptions and projections of Bayer management. Various known and unknown risks, uncertainties and other factors could cause the company’s actual future results, financial condition, development or performance to differ materially from the estimates given here. These factors include factors discussed in Bayer’s public reports, which can be found on the Bayer website at www.bayer.com. The company undertakes no duty to update these forward-looking statements or to conform them to future events or developments.
CKD stage 1-2, according to KDIGO classification, estimated glomerular filtration rate [eGFR] ≥60 ml/min/1.73m
2.
